Resverlogix and EVERSANA Announce Partnership to Support the Pending Launch of the Initial Commercialization of Apabetalone for COVID-19 in the United States and Canada CALGARY, AB and CHICAGO — June 3, 2021 — Resverlogix Corp. ("Resverlogix") (TSX:RVX) and EVERSANA™, the pioneer of next.
CALGARY, Alberta and CHICAGO, June 03, 2021, the pioneer of next generation commercial services to the global life sciences industry, today announced a partnership to support planned commercialization
Article content
CALGARY, Alberta, April 27, 2021 (GLOBE NEWSWIRE) Resverlogix Corp. (“Resverlogix” or the “Company”) (TSX:RVX) announced today the recent publication of an article titled: “
Effect of Apabetalone on Major Adverse Cardiovascular Events in Patients with Chronic Kidney Disease, Type-2 Diabetes Mellitus and Recent Acute Coronary Syndrome: Results from the BETonMACE Randomized Controlled Trial”, in the high-impact, peer-reviewed Clinical Journal of the American Society of Nephrology. The article was accompanied by a peer-reviewed editorial, published in the same journal, titled: “
Novel Therapeutic Options for Cardiovascular Disease with CKD”.
The publication can be viewed HERE, and the accompanying editorial HERE.
“To my knowledge this is the first time that a cardiovascular risk reducing intervention – apabetalone – has shown such an improvement in clinical outcomes in patients with chronic kidney disease (CKD) – defined as an estimated glo
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Resverlogix’s Apabetalone Demonstrates a Medical First in Patients with Chronic Kidney Disease
Resverlogix CorpApril 27, 2021 GMT
CALGARY, Alberta, April 27, 2021 (GLOBE NEWSWIRE) Resverlogix Corp. (“Resverlogix” or the “Company”) (TSX:RVX) announced today the recent publication of an article titled: “
Effect of Apabetalone on Major Adverse Cardiovascular Events in Patients with Chronic Kidney Disease, Type-2 Diabetes Mellitus and Recent Acute Coronary Syndrome: Results from the BETonMACE Randomized Controlled Trial ”, in the high-impact, peer-reviewed Clinical Journal of the American Society of Nephrology. The article was accompanied by a peer-reviewed editorial, published in the same journal, titled: “
Resverlogix’s Apabetalone Demonstrates a Medical First in Patients with Chronic Kidney Disease Apabetalone treatment was associated with a 52% hazard reduction for MACE events such as CVD death and Heart Failure, compared to placebo
April 27, 2021 13:41 ET | Source: Resverlogix Corp Resverlogix Corp Calgary, Alberta, CANADA
CALGARY, Alberta, April 27, 2021 (GLOBE NEWSWIRE) Resverlogix Corp. ( Resverlogix or the Company ) (TSX:RVX) announced today the recent publication of an article titled: “
Effect of Apabetalone on Major Adverse Cardiovascular Events in Patients with Chronic Kidney Disease, Type-2 Diabetes Mellitus and Recent Acute Coronary Syndrome: Results from the BETonMACE Randomized Controlled Trial”, in the high-impact, peer-reviewed Clinical Journal of the American Society of Nephrology. The article was accompanied by a peer-reviewed editorial, published in the same journal, titled: “